DLL4 and ovarian cancer: In a phase I human study (NCT00871559) in patients with advanced ovarian cancer, Enoticumab (REGN421), a Delta-like ligand 4 (Dll4) monoclonal antibody that disrupts Notch-mediated signaling was shown to be a safe agent (Chiorean et al., 2015).